
AFMD
Healthcare · Biotechnology · $3.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2024 | Time not confirmed | -0.95 | -0.94 | +1.4% |
| Sep 5, 2024 | Before the open | -0.89 | -1.01 | -13.5% |
| Jun 12, 2024 | Before the open | -1.43 | -1.27 | +11.2% |
| Mar 28, 2024 | Before the open | -1.54 | -1.35 | +12.3% |
| Nov 14, 2023 | Before the open | -0.18 | -0.16 | +11.1% |
| Aug 10, 2023 | Before the open | -0.19 | -0.20 | -5.3% |
| May 23, 2023 | Before the open | -0.20 | -0.21 | -5.0% |
| Mar 23, 2023 | Before the open | -0.19 | -0.22 | -15.8% |
| Nov 15, 2022 | Before the open | -0.18 | -0.11 | +38.9% |
| Aug 11, 2022 | Before the open | -0.17 | -0.13 | +23.5% |
| Jun 1, 2022 | Before the open | -0.18 | -0.14 | +22.2% |
| Mar 31, 2022 | Before the open | -0.16 | -0.19 | -18.8% |
| Nov 10, 2021 | Before the open | -0.12 |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent,…
| -0.14 |
| -16.7% |
| Jul 1, 2021 | Before the open | -0.09 | 0.01 | +111.1% |
| Apr 15, 2021 | Before the open | -0.04 | -0.17 | -325.0% |
| Nov 10, 2020 | Before the open | -0.08 | -0.07 | +12.5% |
| Aug 11, 2020 | Before the open | -0.13 | -0.16 | -23.1% |
| Jun 23, 2020 | Before the open | -0.13 | -0.11 | +15.4% |
| Nov 19, 2019 | Before the open | -0.16 | -0.17 | -6.3% |
| Aug 7, 2019 | Before the open | -0.12 | -0.17 | -41.7% |
| May 22, 2019 | Before the open | -0.15 | 0.03 | +120.0% |
| Mar 27, 2019 | Before the open | -0.16 | 0.14 | +187.5% |
| Nov 7, 2018 | Before the open | -0.15 | -0.19 | -26.7% |
| Aug 8, 2018 | Before the open | -0.15 | -0.13 | +13.3% |
| May 15, 2018 | Before the open | -0.14 | -0.15 | -7.1% |
| Mar 20, 2018 | Before the open | -0.17 | -0.14 | +17.6% |